Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar;46(3):100742.
doi: 10.1016/j.cpcardiol.2020.100742. Epub 2020 Nov 2.

Thrombosis and Coagulopathy in COVID-19

Juan Esteban Gómez-Mesa, Stephania Galindo-Coral, Maria Claudia Montes, Andrés J Muñoz Martin
Review

Thrombosis and Coagulopathy in COVID-19

Juan Esteban Gómez-Mesa et al. Curr Probl Cardiol. 2021 Mar.

Abstract

Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially occurred in the city of Wuhan, located in China's Hubei province, spread around the world and on March 11, 2020, the World Health Organization declared the new Coronavirus disease 2019 (COVID-19) as a pandemic. The presence of comorbidities (eg, cardiovascular disease, obesity), Sepsis Induced Coagulopathy score >4, elevation of D-dimer (>6 times the normal value), C-reactive protein, troponins and other disseminated intravascular coagulation markers; is associated to a worse prognosis in hospitalized patients with severe COVD-19, reaching a hospital mortality of 42%. Initial anticoagulant treatment with low molecular weight heparin has been shown to reduce mortality by 48% at 7 days and 37% at 28 days and achieve a significant improvement in the arterial oxygen pressure/inspired fraction of O2 (PaO2/FiO2) by mitigating the formation of microthrombi and associated pulmonary coagulopathy.

PubMed Disclaimer

Figures

Graph 1
Graph 1
Daily cases until September/2020. Comparison by regions. Image adapted from: https://covid19.who.int/.
Graph 2
Graph 2
Cumulative cases until September/2020. Comparison by regions. Image adapted from: https://covid19.who.int/.
Graph 3
Graph 3
Worldwide change of the Epicenter of the pandemic: Starting in Asia, then Europe and, currently, America (North America and Latin America). Image adapted from: https://vac-lshtm.shinyapps.io/ncov_tracker/.
See this image and copyright information in PMC

References

    1. Bikdeli B, Madhavan MV, Jimenez D. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020;75:2950–2973. doi: 10.1016/j.jacc.2020.04.031. - DOI - PMC - PubMed
    1. Boccia M, Aronne L, Celia B. COVID-19 and coagulative axis: review of emerging aspects in a novel disease. Monaldi Arch Chest Dis. 2020;90:271–276. doi: 10.4081/monaldi.2020.1300. - DOI - PubMed
    1. Song JC, Wang G, Zhang W. Chinese expert consensus on diagnosis and treatment of coagulation dysfunction in COVID-19. Mil Med Res. 2020;7:19. doi: 10.1186/s40779-020-00247-7. - DOI - PMC - PubMed
    1. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: Interim guidance V 1.2. 2020; 1–21
    1. Günertem E, Akay T, Aliyev A. Treatment and prophylaxis strategies for deep vein thrombosis during COVID-19 outbreak. Turk J Vasc Surg. 2020;29:203–207. doi: 10.9739/tjvs.2020.734. - DOI